Pierrel Research Onco-Immunology

Pierrel Research Onco-Inmunology is a specialized division with more than 10 years of experience, focused on targeted therapies, traditional cytotoxic chemotherapies, radiotherapy, human antibodies, vaccines, stemcell therapy, in vivo diagnostics, supportive and palliative care and onco-immunology drug development with a wide experience in phase I, II, III and IV.

With about 80 professionals worldwide, including projects managers, CTAs, CRAs, physicians, medical writers, drug safety specialists, drug regulatory affairs experts, data managers and eClinical Trial (Hypersuite®) programmers, we have the capabilities to manage oncology clinical trials worldwide. 

Indications

• Solid tumors, NSCLC, SCLC, breast, prostate, mesothelioma and brain tumour
• Haematological malignancies, including non-Hodgkin’s lymphoma and a range of leukaemia, including AML
• Supportive care, including analgesia and antiemetic therapy in cancer patients

Therapeutic expertise

• Oncology
• Immunotherapy
• Biological response modifiers
• Palliative care
• Vaccines